COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS

(Currently amended claims showing deletions ~~by strikethrough~~ or [[double brackets]] and additions by underlining)

1 - 10 (canceled)

11 (currently amended): A ~~compound according to claim 10 wherein said compound is~~ human PTH analogue of the formula, [Cha^{7,11}, des-Met^{8}, Nle^{18}, Tyr^{34}]hPTH(1-34)NH_2 (SEQ ID NO:16), which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

12 - 51 (canceled)

52 (new): A human PTH analogue which selectively binds to the PTH2 receptor, wherein said analogue is selected from the group consisting of

[Cha^{7,11}, des-Met^{8}, Nle^{18}, Tyr^{34}]hPTH(1-34)NH_2 (SEQ ID NO:16),

[Cha^{7,11}, D-Nle^{8}, des-Met^{18}, Tyr^{34}]hPTH(1-34)NH_2, and

[Cha^{7,11}, D-Nle^{8}, Nle^{18}, Tyr^{34}]hPTH(1-34)NH_2,

which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

53 (new): A pharmaceutical composition comprising an analogue according to claim 52 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

54 (new): A method of treating a medical disorder that results from altered or excessive action of the PTH2 receptor, which comprises administering to a patient in need thereof an effective amount of an analogue according to claim 52, sufficient to inhibit the activation of the PTH2 receptor of said patient.

55 (new): A method according to claim 54 wherein said medical disorder is abnormal CNS functions, abnormal pancreatic

functions, divergence from normal mineral metabolism and homeostasis, male infertility, abnormal blood pressure or a hypothalmic disease.